When patients with melanoma become resistant to mitogen-activated protein kinase (MAPK) inhibitor therapy, their tumor cells can upregulate stem cell marker expression including ALDH1 enzymes (Figure S1A).42 The gene discussed is WNK2; the disease is neoplasm.